Our company is built on ground-breaking research from Dr. Jim Wilson’s laboratory at the University of Pennsylvania, now GEMMABio.

 

With strong leadership, and strategic oversight from AS²Bio, MavriX is poised to translate scientific innovation into clinical progress.

 

Our work is focused exclusively on Angelman syndrome—a rare neurogenetic disorder—with the goal of advancing the first investigational gene replacement therapy into clinical trials.